Citius Pharmaceuticals, Inc. (CTXR) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 1.67M | 3.94M | 0 | 0 | 0 | 0 | 155.93K | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | -100% | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 2.05M | 1.36M | 62.04K | 41.37K | 0 | 0 | 155.93K | 52.85K | 52.07K | 51.01K | 49.97K | 49.02K |
| COGS % of Revenue | 122.9% | 34.55% | - | - | - | - | 100% | - | - | - | - | - |
| Gross Profit | -381.89K | 2.58M | -62.04K | -41.37K | 0 | 0 | -53.69K | -52.85K | -52.07K | -51.01K | -49.97K | -49.02K |
| Gross Margin % | -22.9% | 65.45% | - | - | - | - | -34.43% | - | - | - | - | - |
| Gross Profit Growth % | - | - | -15.56% | 21.72% | 100% | 100% | -7.44% | -7.82% | - | -8.1% | -8.04% | -8.09% |
| Operating Expenses | 31.81M | 11.6M | 8.38M | 8.75M | 11.26M | 10.04M | 11.05M | 10.63M | 10.92M | 9.34M | 10.12M | 8.67M |
| OpEx % of Revenue | 1908.05% | 294.13% | - | - | - | - | 7087% | - | - | - | - | - |
| Selling, General & Admin | 26.39M | 5.72M | 1.19M | 7.17M | 7.49M | 7.91M | 8.14M | 7.87M | 7.36M | 6.72M | 7.24M | 4.91M |
| SG&A % of Revenue | 1582.87% | 145.04% | - | - | - | - | 5217.57% | - | - | - | - | - |
| Research & Development | 1.63M | 1.6M | 1.64M | 1.62M | 3.77M | 2.13M | 2.91M | 2.76M | 3.61M | 2.62M | 2.88M | 3.76M |
| R&D % of Revenue | 97.97% | 40.56% | - | - | - | - | 1869.43% | - | - | - | - | - |
| Other Operating Expenses | 1000K | 1000K | 1000K | -41.37K | 0 | 0 | 0 | 0 | -52.07K | 0 | 0 | 0 |
| Operating Income | -32.19M | -9.02M | -8.44M | -8.79M | -11.26M | -10.04M | -11.05M | -10.63M | -10.97M | -9.34M | -10.12M | -8.67M |
| Operating Margin % | -1930.96% | -228.68% | - | - | - | - | -7087% | - | - | - | - | - |
| Operating Income Growth % | -185.9% | 10.16% | 23.65% | 17.36% | -2.65% | -7.48% | -9.14% | -22.63% | -2.67% | -28.84% | -34.11% | 2.74% |
| EBITDA | -30.43M | -8.45M | -8.38M | -8.75M | -11.2M | -9.98M | -11M | -10.58M | -10.92M | -9.29M | -10.07M | -8.62M |
| EBITDA Margin % | -1825.34% | -214.14% | - | - | - | - | -7052.57% | - | - | - | - | - |
| EBITDA Growth % | -171.62% | 15.41% | 23.84% | 17.34% | -2.62% | -7.48% | -9.15% | -22.71% | -2.64% | -28.98% | -34.27% | 2.8% |
| D&A (Non-Cash Add-back) | 1.76M | 573.44K | 62.04K | 41.37K | 56.01K | 54.84K | 53.69K | 52.85K | 52.07K | 51.01K | 49.97K | 49.02K |
| EBIT | -32.19M | -9.02M | -8.38M | -8.77M | -11.26M | -10.02M | -11.05M | -10.63M | -10.97M | -9.34M | -10.12M | -8.67M |
| Net Interest Income | 20.55K | -110.44K | -42.1K | -151.63K | 13.41K | 22.61K | 117.31K | 204.84K | 182.21K | 253.64K | 324.81K | 336.78K |
| Interest Income | 53.58K | 45.1K | 53.42K | 20.64K | 13.41K | 22.61K | 117.31K | 204.84K | 182.21K | 253.64K | 324.81K | 336.78K |
| Interest Expense | 33.03K | 155.54K | 95.52K | 172.26K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 3.85M | -110.44K | -42.1K | -151.63K | 13.41K | 22.61K | 117.31K | 204.84K | 2.57M | 253.64K | 324.81K | 336.78K |
| Pretax Income | -28.34M | -9.13M | -8.48M | -8.94M | -11.25M | -10.02M | -10.93M | -10.43M | -8.4M | -9.09M | -9.8M | -8.34M |
| Pretax Margin % | -1699.81% | -231.48% | - | - | - | - | -7011.76% | - | - | - | - | - |
| Income Tax | -231.21K | 264.24K | 264.24K | 264.24K | 264.24K | 264.24K | 144K | 144K | 144K | 144K | 144K | 144K |
| Effective Tax Rate % | 0.82% | -2.89% | -3.12% | -2.96% | -2.35% | -2.64% | -1.32% | -1.38% | -1.71% | -1.58% | -1.47% | -1.73% |
| Net Income | -21.23M | -8.22M | -7.96M | -8.79M | -10.92M | -9.77M | -10.79M | -10.57M | -8.54M | -9.23M | -9.94M | -8.48M |
| Net Margin % | -1273.39% | -208.43% | - | - | - | - | -6920.05% | - | - | - | - | - |
| Net Income Growth % | -94.49% | 15.84% | 26.24% | 16.87% | -27.77% | -5.82% | -8.51% | -24.7% | 18.83% | -156.88% | -24.44% | 3.76% |
| Net Income (Continuing) | -28.11M | -9.39M | -8.74M | -9.2M | -11.51M | -10.28M | -11.08M | -10.57M | -8.54M | -9.23M | -9.94M | -8.48M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 7.54M | 13.51M | 9.98M | 2.5M | 2.92M | 3.51M | 4.02M | 600.38K | 600.38K | 600.38K | 600.38K | 600.38K |
| EPS (Diluted) | -0.95 | -0.38 | -0.44 | -0.80 | -1.27 | -1.30 | -1.70 | -1.57 | -1.34 | -1.45 | -0.06 | -0.06 |
| EPS Growth % | 25.2% | 70.77% | 74.12% | 49.04% | 5.22% | 10.34% | -2615.65% | -2749.36% | -1761.11% | -5794.31% | -14.44% | 8.62% |
| EPS (Basic) | -0.95 | -0.38 | -0.44 | -0.80 | -1.27 | -1.30 | -1.59 | -1.57 | -1.34 | -1.45 | -0.06 | -0.06 |
| Diluted Shares Outstanding | 22.38M | 21.5M | 18.07M | 11.01M | 11.59M | 11.59M | 11.59M | 11.59M | 10.6M | 10.6M | 10.59M | 10.25M |
| Basic Shares Outstanding | 22.38M | 21.5M | 18.07M | 11.01M | 11.59M | 11.59M | 11.59M | 11.59M | 10.6M | 10.6M | 10.59M | 10.25M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - |